NASDAQ:DRTS Alpha Tau Medical (DRTS) Stock Forecast, Price & News $3.47 -0.12 (-3.34%) (As of 11:31 AM ET) Add Compare Share Share Today's Range$3.47▼$3.6050-Day Range$2.95▼$3.9752-Week Range$2.75▼$5.95Volume15,825 shsAverage Volume62,290 shsMarket Capitalization$240.71 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Alpha Tau Medical MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside322.7% Upside$14.67 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.50) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector280th out of 976 stocksSurgical & Medical Instruments Industry40th out of 99 stocks 3.5 Analyst's Opinion Consensus RatingAlpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.67, Alpha Tau Medical has a forecasted upside of 322.7% from its current price of $3.47.Amount of Analyst CoverageAlpha Tau Medical has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.32% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently decreased by 22.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpha Tau Medical does not currently pay a dividend.Dividend GrowthAlpha Tau Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRTS. Previous Next 4.1 News and Social Media Coverage News SentimentAlpha Tau Medical has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alpha Tau Medical this week, compared to 0 articles on an average week.Search Interest5 people have searched for DRTS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.47% of the stock of Alpha Tau Medical is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.50) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpha Tau Medical is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpha Tau Medical is -10.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpha Tau Medical has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alpha Tau Medical (NASDAQ:DRTS) StockAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Read More DRTS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRTS Stock News HeadlinesSeptember 16, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Alpha Tau Medical's (NASDAQ:DRTS) Cash Burn SituationSeptember 14, 2023 | stockhouse.comAlpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical CenterOctober 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 24, 2023 | finance.yahoo.comAlpha Tau Medical to Participate in September Investor ConferencesAugust 17, 2023 | finance.yahoo.comAlpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRTAugust 2, 2023 | finance.yahoo.comAlpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023May 25, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)May 24, 2023 | finance.yahoo.comAlpha Tau Medical to Participate in June Investor ConferencesOctober 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 23, 2023 | msn.comRecap: Alpha Tau Medical Q1 EarningsMay 22, 2023 | finance.yahoo.comShould You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?May 18, 2023 | markets.businessinsider.comAlpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. WainwrightMay 17, 2023 | finance.yahoo.comAlpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge UniversityMay 11, 2023 | finance.yahoo.comAlpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network OpenMay 3, 2023 | finance.yahoo.comAlpha Tau Medical to Present at Guggenheim Radiopharmaceuticals DayApril 24, 2023 | msn.comAlpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapyMarch 8, 2023 | finance.yahoo.comAlpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) TrialMarch 1, 2023 | finance.yahoo.comAlpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver MetastasesDecember 13, 2022 | finance.yahoo.comAlpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023November 23, 2022 | finanznachrichten.deAlpha Tau Medical Ltd.: Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 9, 2022 | finance.yahoo.comAlpha Tau to Present at Upcoming November Investor ConferencesOctober 21, 2022 | finance.yahoo.comAlpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation OncologySeptember 24, 2022 | seekingalpha.comDRTS Alpha Tau Medical Ltd.September 19, 2022 | finance.yahoo.comAlpha Tau Medical Ltd.'s (NASDAQ:DRTS) largest shareholders are individual investors with 47% ownership, insiders own 26%September 8, 2022 | finance.yahoo.comAlpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic TherapySeptember 1, 2022 | finance.yahoo.comAlpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial OfficerAugust 30, 2022 | finance.yahoo.comAlpha Tau Medical to Participate in Upcoming September Investor ConferencesSee More Headlines Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address DRTS Company Calendar Last Earnings8/28/2023Today10/03/2023Next Earnings (Estimated)11/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRTS CUSIPN/A CIK1871321 Webhealthcarecapitalcorp.com Phone972-3577-4115FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.67 High Stock Price Forecast$23.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+308.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.64% Return on Assets-19.62% Debt Debt-to-Equity RatioN/A Current Ratio17.74 Quick Ratio18.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book2.27Miscellaneous Outstanding Shares69,370,000Free Float41,971,000Market Cap$249.04 million OptionableNot Optionable Beta0.93 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Uzi Sofer (Age 53)CEO & Chairman Comp: $1.58MMr. Raphi Levy (Age 38)Chief Financial Officer Comp: $1.24MMr. Amnon Gat (Age 48)Chief Operations Officer Comp: $497kMr. Ronen Segal (Age 50)Chief Technology Officer Comp: $380kDr. Robert B. Den M.D. (Age 44)Chief Medical Officer & Member of Scientific Advisory Board Comp: $565kProf. Yona Keisari (Age 76)Chief Scientific Officer & Member of Scientific Advisory board Ms. Rebecca BeckerVP of legalMr. Peter M. Melnyk (Age 61)Chief Commercial Officer Prof. Itzhak Kelson (Age 83)Chief Physics Officer & Member of Scientific Advisory Board Ms. Yael Zeiger (Age 40)Corp. Controller More ExecutivesKey CompetitorsDBV TechnologiesNASDAQ:DBVTAtara BiotherapeuticsNASDAQ:ATRAOcular TherapeutixNASDAQ:OCULPardes BiosciencesNASDAQ:PRDSParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Sold 19,397 shares on 8/11/2023Ownership: 0.057%Geode Capital Management LLCBought 6,470 shares on 8/11/2023Ownership: 0.048%Citigroup Inc.Bought 313,657 shares on 8/10/2023Ownership: 0.489%Atalaya Capital Management LPBought 73,742 shares on 8/9/2023Ownership: 0.107%Levin Capital Strategies L.P.Bought 20,000 shares on 7/31/2023Ownership: 0.029%View All Institutional Transactions DRTS Stock - Frequently Asked Questions Should I buy or sell Alpha Tau Medical stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRTS shares. View DRTS analyst ratings or view top-rated stocks. What is Alpha Tau Medical's stock price forecast for 2023? 3 analysts have issued 1 year price objectives for Alpha Tau Medical's shares. Their DRTS share price forecasts range from $9.00 to $23.00. On average, they anticipate the company's share price to reach $14.67 in the next twelve months. This suggests a possible upside of 308.5% from the stock's current price. View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts. How have DRTS shares performed in 2023? Alpha Tau Medical's stock was trading at $3.18 at the beginning of 2023. Since then, DRTS stock has increased by 12.9% and is now trading at $3.59. View the best growth stocks for 2023 here. Are investors shorting Alpha Tau Medical? Alpha Tau Medical saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 122,200 shares, a decline of 22.9% from the August 31st total of 158,500 shares. Based on an average daily volume of 70,200 shares, the short-interest ratio is currently 1.7 days. Currently, 0.3% of the company's shares are short sold. View Alpha Tau Medical's Short Interest. When is Alpha Tau Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023. View our DRTS earnings forecast. How were Alpha Tau Medical's earnings last quarter? Alpha Tau Medical Ltd. (NASDAQ:DRTS) posted its quarterly earnings data on Monday, August, 28th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). What is Alpha Tau Medical's stock symbol? Alpha Tau Medical trades on the NASDAQ under the ticker symbol "DRTS." How do I buy shares of Alpha Tau Medical? Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alpha Tau Medical's stock price today? One share of DRTS stock can currently be purchased for approximately $3.59. How much money does Alpha Tau Medical make? Alpha Tau Medical (NASDAQ:DRTS) has a market capitalization of $249.04 million. The company earns $-33,760,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. How can I contact Alpha Tau Medical? Alpha Tau Medical's mailing address is 301 N. MARKET STREET STE 1414, WILMINGTON DE, 19801. The official website for the company is healthcarecapitalcorp.com. The company can be reached via phone at 972-3577-4115 or via email at ir@alphatau.com. This page (NASDAQ:DRTS) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.